2,2-diphenyl-butyric acid amide | 5466-38-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,2-diphenyl-butyric acid amide
• 英文别名: 2,2-Diphenyl-buttersaeure-amid；2,2-Diphenylbutanamide
• CAS: 5466-38-6
• 化学式: C₁₆H₁₇NO
• 分子量: 239.317
• InChiKey: YEUNWXVEHKUOBQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  18
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.19
• 拓扑面积：
  43.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  亚硝酸丁酯 、 2,2-diphenyl-butyric acid amide 生成 2,2-二苯基丁酸
  参考文献：
  名称：

  Basic Esters and Amides of α-Substituted Diphenylacetic Acids

  摘要：

  DOI：

  10.1021/ja01163a057
• 作为产物：
  描述：

  2,2-二苯基丁腈 在 硫酸 、 溶剂黄146 作用下， 生成 2,2-diphenyl-butyric acid amide
  参考文献：
  名称：

  Basic Esters and Amides of α-Substituted Diphenylacetic Acids

  摘要：

  DOI：

  10.1021/ja01163a057

文献信息

• [EN] PHENYL SUBSTITUTED PIPERIDINE COMPOUNDS FOR USE AS PPAR ACTIVATORS<br/>[FR] COMPOSES DE PIPERIDINE PHENYLE A SUBSTITUTION PHENYLE S'UTILISANT COMME ACTIVATEURS DE PPAR
  申请人：PFIZER PROD INC

  公开号：WO2004048334A1

  公开（公告）日：2004-06-10

  PPAR alpha activators, pharmaceutical compositions containing such compounds and the use of such compounds to elevate certain plasma lipid levels, including high density lipoprotein-cholesterol and to lower certain other plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by low levels of HDL cholesterol and/or high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.

  PPARα激动剂，含有这类化合物的药物组合物以及利用这类化合物提高特定血浆脂质水平，包括高密度脂蛋白胆固醇，并降低其他特定血浆脂质水平，如低密度脂蛋白胆固醇和甘油三酯，并据此治疗由高密度脂蛋白胆固醇水平低和/或低密度脂蛋白胆固醇和甘油三酯水平高加重的疾病，如动脉粥样硬化和心血管疾病，在哺乳动物，包括人类中的应用。
• ORGANIC COMPOUNDS
  申请人：Breitenstein Werner

  公开号：US20090233920A1

  公开（公告）日：2009-09-17

  The invention relates to 3,5-substituted piperidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (=disorder) that depends on activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; pharmaceutical formulations comprising a 3,5-substituted piperidine compound, and/or a method of treatment comprising administering a 3,5-substituted piperidine compound, a method for the manufacture of a 3,5-substituted piperidine compound, and novel intermediates and partial steps for its synthesis. The preferred compounds (which can also be present as salts) have the formula I wherein R1, R2, T, R3 and R4 are as defined in the specification.

  该发明涉及3,5-取代哌啶化合物，这些化合物用于诊断和治疗温血动物，特别是用于治疗依赖肾素活性的疾病（=紊乱）；该类化合物用于制备用于治疗依赖肾素活性疾病的药物配方；该类化合物用于治疗依赖肾素活性的疾病；包括3,5-取代哌啶化合物的药物配方，和/或包括给予3,5-取代哌啶化合物的治疗方法，一种用于制造3,5-取代哌啶化合物的方法，以及其合成的新中间体和部分步骤。优选的化合物（也可以存在为盐）具有式I的结构，其中R1、R2、T、R3和R4如规范中定义。
• M3 muscarinic acetylchoine receptor antagonists
  申请人：Busch-Petersen Jakob

  公开号：US20070185148A1

  公开（公告）日：2007-08-09

  Muscarinic Acetylcholine receptor antagonists and methods of using them are provided.

  提供了肌碱乙酰胆碱受体拮抗剂及其使用方法。
• 1-Pyridin-4-yl-urea derivatives
  申请人：Aissaoui Hamed

  公开号：US20060094716A1

  公开（公告）日：2006-05-04

  The invention relates to novel 1-pyridin-4-yl urea derivatives and related compounds and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including processes for the preparation of the compounds, pharmaceutical compositions containing one or more of those compounds and especially their use as neurohormonal antagonists.

  本发明涉及新型的1-吡啶-4-基脲衍生物及其相关化合物，以及将其用作制备药物组合物中的活性成分。本发明还涉及相关方面，包括制备该化合物的过程，含有其中一个或多个化合物的药物组合物，特别是它们作为神经激素拮抗剂的用途。
• Method for the treatment or prevention of respiratory disorders with a cyclooxygenase-2 inhibitor in combination with a muscarinic receptor antagonist and compositions therewith
  申请人：Seibert Karen

  公开号：US20050107349A1

  公开（公告）日：2005-05-19

  The present invention relates to a novel method of preventing and/or treating respiratory disorders and respiratory disorder-related complications in a subject by administering to the subject at least one Cox-2 inhibitor in combination with one or more muscarinic receptor antagonists. Compositions, pharmaceutical compositions and kits are also described.

  本发明涉及一种新的方法，通过给予受试者至少一种Cox-2抑制剂和一种或多种肌肉性受体拮抗剂的组合，预防和/或治疗呼吸系统疾病及其相关并发症。还描述了组合物、制药组合物和工具包。